Tumor immunology deals with the natural or therapy-induced recognition of cancers, as well as with the intricate interplay between oncogenesis, inflammation and immunosurveillance. This high-profile journal, OncoImmunology, specifically deals with tumor immunology. Recent progress has allowed for the first clinical demonstration (and FDA approval) of anticancer immunotherapies. There is also an ever-growing suspicion that—unexpectedly—many of the currently used chemotherapeutic agents depend in their efficacy on the active contribution of immune effectors. To use a drastic metaphor, oncologists who applied successful chemotherapeutic (or radiotherapeutic) regimens have taken advantage of the immune system's capacity to recognize tumor-specific or tumor-associated antigens and to control cancer (stem) cell growth, without being aware of the invisible helping hands. As a result, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies. There is also a strong rationale in favor of combining conventional anticancer therapies with immunotherapies.
OncoImmunology accepts high-profile submissions in the fundamental, translational and clinical areas of tumor immunology. Submissions dealing with solid or hematological cancers, inflammation, innate and acquired immune responses are welcome.
OncoImmunology publishes Original Research Articles, Brief Reports, Reviews, Commentaries and Meeting Reports in this area of research.
Why publish with us?
- Increase your opportunities for future collaboration
- Validate your research with our robust peer review process
- Increase the impact of your research with PubMed Central listings and more
- Gain recognition with a broad and international readership
- Receive 50 free e-prints & promotional tips on promoting your article courtesy of our Author Resources site
- Immediately see the impact of your research made in the community: track downloads, citations, and the Altmetric Score of your article on My Authored Works.
Please read our Instructions for Authors for details on preparing your manuscript.
Submit your final manuscript online here.
The immune monitoring community has recently established the consensus framework MIATA (“Minimal Information About T Cell Assays”) for reporting of T-cell assay results, which promote objective and thorough interpretation of data and the comparability of results. OncoImmunology supports and encourages the implementation of the MIATA guidelines.
- Editor-in-Chief: Lorenzo Galluzzi, University Paris Descartes, Paris, FR
- Editor-in-Chief: Guido Kroemer, University of Paris Descartes, Paris, FR
- Editor-in-Chief: Laurence Zitvogel, INSERM, Institut Gustave Roussy, Villejuif, FR